Ablynx NV of Ghent, Belgium, which is developing a new class of antibody-derived therapeutic proteins called Nanobodies, said that revenues for the first quarter of 2008 were €3.3 million, up by 53% compared with €2.1 million a year earlier. ---Subscribe to MedNous to access this article--- Company News
